Your browser doesn't support javascript.
Serum levels of ACE2 are higher in patients with obesity and diabetes.
Emilsson, Valur; Gudmundsson, Elias F; Aspelund, Thor; Jonsson, Brynjolfur G; Gudjonsson, Alexander; Launer, Lenore J; Lamb, John R; Gudmundsdottir, Valborg; Jennings, Lori L; Gudnason, Vilmundur.
  • Emilsson V; Icelandic Heart Association Kopavogur Iceland.
  • Gudmundsson EF; Faculty of Medicine University of Iceland Reykjavik Iceland.
  • Aspelund T; Icelandic Heart Association Kopavogur Iceland.
  • Jonsson BG; Icelandic Heart Association Kopavogur Iceland.
  • Gudjonsson A; Icelandic Heart Association Kopavogur Iceland.
  • Launer LJ; Icelandic Heart Association Kopavogur Iceland.
  • Lamb JR; Laboratory of Epidemiology and Population Sciences Intramural Research Program National Institute on Aging Bethesda MD USA.
  • Gudmundsdottir V; GNF Novartis San Diego CA USA.
  • Jennings LL; Icelandic Heart Association Kopavogur Iceland.
  • Gudnason V; Faculty of Medicine University of Iceland Reykjavik Iceland.
Obes Sci Pract ; 7(2): 239-243, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-986356
ABSTRACT

OBJECTIVE:

As severity of outcome in COVID-19 is disproportionately higher among individuals with obesity, smokers, patients with hypertension, kidney disease, chronic pulmonary disease, coronary heart disease (CHD), and/or type 2 diabetes (T2D), serum levels of ACE2, the cellular entry point for the coronavirus SARS-CoV-2, were examined in these high-risk groups.

METHODS:

Associations of ACE2 levels to smokers and patients with hypertension, T2D, obesity, CHD, or COPD were investigated in a single center population-based study of 5457 Icelanders from the Age, Gene/Environment Susceptibility Reykjavík Study (AGES-RS) of the elderly (mean age 75 ± 6 years), using multiple linear regression analysis.

RESULTS:

Serum levels of ACE2 were higher in smokers and individuals with T2D and/or obesity while they were unaffected in the other patient groups.

CONCLUSION:

ACE2 levels are higher in some patient groups with comorbidities linked to COVID-19 including obesity and T2D and as such may have an emerging role as a circulating biomarker for severity of outcome in the disease.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Language: English Journal: Obes Sci Pract Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Language: English Journal: Obes Sci Pract Year: 2021 Document Type: Article